In this review, we discuss several potential targets within T cells, including SH2B3/LNK, SGK1, ROCK2, immunometabolic pathways, and checkpoint inhibitors, that could potentially be exploited to modulate T-cell phenotype and function for the treatment of hypertension and related cardiovascular diseases. This evidence concerns the gene SH2B3 and cardiovascular disorder.